Diamyd® diabetes vaccine to be used in prevention study
Today Diamyd Medical reported that a team of Nordic researchers has applied for
permission to begin a study using the Diamyd® diabetes vaccine to vaccinate
people at risk of developing type 1 diabetes.
The study's objective is to study the cause and mechanism of the disease process
that results in type 1 diabetes, and how the disease can be prevented.
Participants will be divided into different groups: a control group, and a group
treated with Diamyd®. The normal disease process will be compared with the same
process after vaccination with Diamyd®.
The Phase II results for the treatment of newly diagnosed children and
adolescents with Diamyd® were published on October 30 in the New England Journal
of Medicine. The results indicate that efficacy is best with early treatment.
Because the disease develops by the immune system gradually destroying the cells
that form insulin, it is probable that the development of type 1 diabetes can be
prevented, or at least delayed, by vaccinating with Diamyd® before the disease
strikes."This is the first time our Diamyd® diabetes vaccine will be used in a
prevention study with the objective of preventing type 1 diabetes," says
Elisabeth Lindner, President and CEO of Diamyd Medical. "This is a tremendous
step for the Diamyd® diabetes vaccine."
The Diamyd® vaccine is already being tested in the company's own Phase III
studies of children and adolescents with recent onset type 1 diabetes in Europe
and the US. The first findings, which should result in a market application for
the Diamyd® diabetes vaccine, are expected to be available in fall 2010. At the
same time, Diamyd Medical is developing additional diabetes-related products,
including products for LADA (Latent Autoimmune Diabetes in Adults) and products
for diabetes-related complications.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
elisabeth.lindner@diamyd.com
Phone: +46-8-661 00 26
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.),
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. VATno: SE556530-142001.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials are ongoing in both the US and Europe.
Furthermore, the company has initiated clinical studies within chronic pain,
using its Nerve Targeting Drug Delivery System (NTDDS). The company has also
out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
